Asia Pacific bioanalytical testing services market will grow by 11.2% annually with a total addressable market cap of $ 13,359.1 million over 2022-2031, driven by the rising demand for analytical testing of biologics and biosimilars amid COVID-19 pandemic, increasing preference for outsourcing analytical testing, growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, and the rising adoption of the Quality by Design (QbD) approach.
Highlighted with 36 tables and 78 figures, this 136-page report 鈥淎sia Pacific Bioanalytical Testing Services 麻豆原创 2021-2031 by Molecule Type (Small, Large), Application (Bioavailability and Bioequivalence, PK, PD, ADME), Test Type (Cell-based, Virology, SINA, MDOV, Biomarker), Workflow Process (Sample Preparation, Sample Analysis, Others), Therapeutic Area (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User (Pharma and Biopharma Companies, CDMOs, CROs), and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific bioanalytical testing services market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific bioanalytical testing services market in every aspect of the classification from perspectives of Molecule Type, Application, Test Type, Workflow Process, Therapeutic Area, End User, and Country.
Based on Molecule Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Small Molecules
鈥� Large Molecules
o LC-MS Studies
o Immunoassays
o Other Large Molecule Tests
Based Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Bioavailability and Bioequivalence Studies
鈥� Pharmacokinetics (PK)
鈥� Pharmacodynamics (PD)
鈥� Absorption, Distribution, Metabolism, Excretion (ADME)
鈥� Other Applications
By Test Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Cell-based Assays
o Bacterial Cell-based Assays
o Viral Cell-based Assays
鈥� Virology Testing
o In Vitro Virology Testing
o In Vivo Virology Testing
o Species-Specific Viral PCR Assays
鈥� Serology, Immunogenicity, and Neutralizing Antibodies (SINA)
o Bacterial Serology, Immunogenicity, and Neutralizing Antibodies
o Viral Serology, Immunogenicity, and Neutralizing Antibodies
鈥� Method Development Optimization and Validation (MDOV)
鈥� Biomarker Testing
鈥� Pharmacokinetic Testing
鈥� Other Test Types
By Workflow Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Sample Preparation
o Protein Precipitation
o Liquid-liquid Extraction (LLE)
鈥� Sample Analysis
o Hyphenated Technique
o Chromatographic Technique
o Electrophoresis
o Ligand Binding Assay
o Mass Spectrometry
o Nuclear Magnetic Resonance
鈥� Other Workflow Processes
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Oncology
鈥� Neurology
鈥� Infectious Diseases
鈥� Gastroenterology
鈥� Cardiology
鈥� Other Therapeutic Areas
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Pharma and Biopharma Companies
鈥� Contract Development and Manufacturing Organizations (CDMOs)
鈥� Contract Research Organizations (CROs)
Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Workflow Process, and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Charles River Laboratories International Inc.
Covance Inc.
Eurofins Scientific
ICON PLC
Intertek Group PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America Holdings
Medpace Holdings, Inc.
Pace Analytical Services LLC.
Parexel International Corporation
PPD Inc.
SGS SA
Syneos Health, LLC
Toxikon Corporation
WuXi Apptech Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of 麻豆原创 Research Methodology 12
1.2.2 麻豆原创 Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 28
2.3 麻豆原创 Restraints and Challenges 31
2.4 Emerging Opportunities and 麻豆原创 Trends 34
2.5 Porter鈥檚 Fiver Forces Analysis 38
3 Segmentation of Asia Pacific 麻豆原创 by Molecule Type 42
3.1 麻豆原创 Overview by Molecule Type 42
3.2 Small Molecules 44
3.3 Large Molecules 45
3.3.1 LC-MS Studies 46
3.3.2 Immunoassays 47
3.3.3 Other Large Molecule Tests 48
4 Segmentation of Asia Pacific 麻豆原创 by Application 49
4.1 麻豆原创 Overview by Application 49
4.2 Bioavailability and Bioequivalence Studies 51
4.3 Pharmacokinetics (PK) 52
4.4 Pharmacodynamics (PD) 53
4.5 Absorption, Distribution, Metabolism, Excretion (ADME) 54
4.6 Other Applications 55
5 Segmentation of Asia Pacific 麻豆原创 by Test Type 56
5.1 麻豆原创 Overview by Test Type 56
5.2 Cell-based Assays 58
5.2.1 Bacterial Cell-based Assays 59
5.2.2 Viral Cell-based Assays 60
5.3 Virology Testing 61
5.3.1 In Vitro Virology Testing 62
5.3.2 In Vivo Virology Testing 63
5.3.3 Species-Specific Viral PCR Assays 64
5.4 Serology, Immunogenicity, and Neutralizing Antibodies (SINA) 65
5.4.1 Bacterial Serology, Immunogenicity, and Neutralizing Antibodies 66
5.4.2 Viral Serology, Immunogenicity, and Neutralizing Antibodies 67
5.5 Method Development Optimization and Validation (MDOV) 68
5.6 Biomarker Testing 69
5.7 Pharmacokinetic Testing 70
5.8 Other Test Types 71
6 Segmentation of Asia Pacific 麻豆原创 by Workflow Process 72
6.1 麻豆原创 Overview by Workflow Process 72
6.2 Sample Preparation 74
6.2.1 Protein Precipitation 75
6.2.2 Liquid-liquid Extraction (LLE) 76
6.2.3 Solid Phase Extraction (SPE) 77
6.3 Sample Analysis 78
6.3.1 Hyphenated Technique 80
6.3.2 Chromatographic Technique 81
6.3.3 Electrophoresis 82
6.3.4 Ligand Binding Assay 83
6.3.5 Mass Spectrometry 84
6.3.6 Nuclear Magnetic Resonance 85
6.4 Other Workflow Processes 86
7 Segmentation of Asia Pacific 麻豆原创 by Therapeutic Area 87
7.1 麻豆原创 Overview by Therapeutic Area 87
7.2 Oncology 89
7.3 Neurology 90
7.4 Infectious Diseases 91
7.5 Gastroenterology 92
7.6 Cardiology 93
7.7 Other Therapeutic Areas 94
8 Segmentation of Asia Pacific 麻豆原创 by End User 95
8.1 麻豆原创 Overview by End User 95
8.2 Pharma and Biopharma Companies 97
8.3 Contract Development and Manufacturing Organizations (CDMOs) 98
8.4 Contract Research Organizations (CROs) 99
9 Asia-Pacific 麻豆原创 2021-2031 by Country 100
9.1 Overview of Asia-Pacific 麻豆原创 100
9.2 Japan 103
9.3 China 106
9.4 Australia 108
9.5 India 110
9.6 South Korea 112
9.7 Rest of APAC Region 114
10 Competitive Landscape 116
10.1 Overview of Key Vendors 116
10.2 New Product Launch, Partnership, Investment, and M&A 119
10.3 Company Profiles 120
Charles River Laboratories International Inc. 120
Covance Inc. 122
Eurofins Scientific 123
ICON PLC 124
Intertek Group PLC 125
IQVIA Holdings, Inc. 126
Laboratory Corporation of America Holdings 127
Medpace Holdings, Inc. 128
Pace Analytical Services LLC. 129
Parexel International Corporation 130
PPD Inc. 131
SGS SA 132
Syneos Health, LLC 133
Toxikon Corporation 134
WuXi Apptech Co., Ltd. 135
RELATED REPORTS 136
Selected Key Players:
Charles River Laboratories International Inc.
Covance Inc.
Eurofins Scientific
ICON PLC
Intertek Group PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America Holdings
Medpace Holdings, Inc.
Pace Analytical Services LLC.
Parexel International Corporation
PPD Inc.
SGS SA
Syneos Health, LLC
Toxikon Corporation
WuXi Apptech Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
